NCT00747825View on ClinicalTrials.gov

Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Metastatic Melanoma
Interventions
DRUG

131-I-MIP-1145

IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145

Trial Locations (1)

19104-4283

Hospital of the University of Pennsylvania, Philadelphia

Sponsors
All Listed Sponsors
lead

Molecular Insight Pharmaceuticals, Inc.

INDUSTRY

NCT00747825 - Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma | Biotech Hunter | Biotech Hunter